NEW YORK, April 24, 2024 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating therapeutic cancer vaccines based on its T-win® platform, today announced the acceptance of an abstract related to IO102-IO103, the company’s lead investigational therapeutic cancer vaccine candidate, for presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting, taking place in Chicago May 31-June 4, 2024. A trial-in-progres
Marjan Shamsaei, PharmD, Newly Appointed as Senior Vice President, Commercial Development and Portfolio Lead Brings Deep Oncology Product Commercialization ExpertiseNEW YORK, April 15, 2024 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating therapeutic cancer vaccines based on its T-win® platform, today announced that Marjan Shamsaei, PharmD, joined the company as SVP, Commercial Development and Portfolio Lead for IO102-I
Non-Clinical Poster Data Support the Use of Dual Antigen Approach to Enhance Anti-Tumor ActivityNEW YORK, April 09, 2024 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating therapeutic cancer vaccines based on its T-win® platform, today shared new data related to the company’s lead therapeutic cancer vaccine candidate, IO102-IO103, at the American Association for Cancer Research (AACR) Annual Meeting 2024, taking place Apr